» Articles » PMID: 25189355

RSK Promotes Prostate Cancer Progression in Bone Through ING3, CKAP2, and PTK6-mediated Cell Survival

Overview
Journal Mol Cancer Res
Specialty Cell Biology
Date 2014 Sep 6
PMID 25189355
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Prostate cancer has a proclivity to metastasize to bone. The mechanism by which prostate cancer cells are able to survive and progress in the bone microenvironment is not clear. Identification of molecules that play critical roles in the progression of prostate cancer in bone will provide essential targets for therapy. Ribosomal S6 protein kinases (RSK) have been shown to mediate many cellular functions critical for cancer progression. Whether RSK plays a role in the progression of prostate cancer in bone is unknown. IHC analysis of human prostate cancer specimens showed increased phosphorylation of RSK in the nucleus of prostate cancer cells in a significant fraction of human prostate cancer bone metastasis specimens, compared with the primary site or lymph node metastasis. Expression of constitutively active myristylated RSK in C4-2B4 cells (C4-2B4/RSK) increased their survival and anchorage-independent growth compared with C4-2B4/vector cells. Using an orthotopic bone injection model, it was determined that injecting C4-2B4/RSK cells into mouse femurs enhanced their progression in bone compared with control cells. In PC3-mm2 cells, knockdown of RSK1 (RPS6KA1), the predominant RSK isoform, but not RSK2 (RPS6KA2) alone, decreased anchorage-independent growth in vitro and reduced tumor progression in bone and tumor-induced bone remodeling in vivo. Mechanistic studies showed that RSK regulates anchorage-independent growth through transcriptional regulation of factors that modulate cell survival, including ING3, CKAP2, and PTK6. Together, these data provide strong evidence that RSK is an important driver in prostate cancer progression in bone.

Implications: RSK, an important driver in prostate cancer progression in bone, has promising potential as a therapeutic target for prostate cancer bone metastasis.

Citing Articles

RSK1 and RSK2 as therapeutic targets: an up-to-date snapshot of emerging data.

Spirrison A, Lannigan D Expert Opin Ther Targets. 2024; 28(12):1047-1059.

PMID: 39632509 PMC: 11801519. DOI: 10.1080/14728222.2024.2433123.


The Protective Effects of an Aged Black Garlic Water Extract on the Prostate.

Libero M, Montero-Hidalgo A, Recinella L, Luque R, Generali D, Acquaviva A Nutrients. 2024; 16(17).

PMID: 39275340 PMC: 11396974. DOI: 10.3390/nu16173025.


The spindle protein CKAP2 regulates microtubule dynamics and ensures faithful chromosome segregation.

Paim L, Lopez-Jauregui A, McAlear T, Bechstedt S Proc Natl Acad Sci U S A. 2024; 121(9):e2318782121.

PMID: 38381793 PMC: 10907244. DOI: 10.1073/pnas.2318782121.


Elucidation of the genetic determination of clutch traits in Chinese local chickens of the Laiwu Black breed.

Wang J, Liu Z, Cao D, Liu J, Li F, Han H BMC Genomics. 2023; 24(1):686.

PMID: 37968610 PMC: 10652520. DOI: 10.1186/s12864-023-09798-0.


Evaluation of Pathogenicity and Structural Alterations for the Mutations Identified in the Conserved Region of the C-Terminal Kinase Domain of Human-Ribosomal S6 Kinase 1.

Chikhale V, Goswami N, Khan M, Borah P, Varma A ACS Omega. 2023; 8(18):16273-16283.

PMID: 37179615 PMC: 10173430. DOI: 10.1021/acsomega.3c00722.


References
1.
Hall C, Zhang H, Baile S, Ljungman M, Kuhstoss S, Keller E . p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res. 2010; 70(23):9916-26. PMC: 3059079. DOI: 10.1158/0008-5472.CAN-10-0440. View

2.
Ostrander J, Daniel A, Lange C . Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol. 2010; 10(6):662-9. PMC: 2981671. DOI: 10.1016/j.coph.2010.08.007. View

3.
Nagashima M, Shiseki M, Pedeux R, Okamura S, Kitahama-Shiseki M, Miura K . A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene. 2003; 22(3):343-50. DOI: 10.1038/sj.onc.1206115. View

4.
Zhao Y, Bjorbaek C, Weremowicz S, Morton C, Moller D . RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation. Mol Cell Biol. 1995; 15(8):4353-63. PMC: 230675. DOI: 10.1128/MCB.15.8.4353. View

5.
Wu C, Liu S, Lee Y, Wang R, Sun S, Yin F . RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B. Oncogene. 2013; 33(18):2385-94. PMC: 4026278. DOI: 10.1038/onc.2013.182. View